All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Long-term survival with oral azacitidine: An update from the QUAZAR AML-001 trial
Updated results from the QUAZAR AML-001 trial demonstrated that treatment with oral azacitidine led to improved LTS outcomes compared with placebo (34.9% vs 24.4%)....
Neutralizing antibody responses to SARS-CoV-2 in patients with AML or MDS
Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) represents an increased risk for patients with immune dysfunction despite vaccination. There is currently an under...
"The AML Hub is a trusted, respected, and comprehensive resource where clinicians and researchers interested in AML can confidently learn about the most exciting and novel clinical and biological advances in the field."
Are you a healthcare professional? What is your speciality?
Please select or type your speciality
By sharing this information, you can help ensure we continue to develop content that is of most relevance for our audience.
Thank you for submitting.